AQSTAquestive Therapeutics, Inc.
$4.77-20% 1Y
$4.77
$2.9552 weeks$7.49
AQST in its own filings
AQST's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
245
Events found in the filings · across 677 filings · the record starts in 2018
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 29, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 26, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Delisting notice / listing-rule failure2 occurrences
- 2023-01-03
- SEC comment-letter activity25 occurrences
- 2024-04-19
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 29, 2026, Aquestive Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has elected Richard J. Daly as a director of the Company, effective October 14, 2026.Director or officer change · Form 8-K
- Sep 17, 2026On September 17, 2026, the Company issued a press release announcing it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis.Regulation FD disclosure · Form 8-K
- Aug 11, 2026Aquestive Therapeutics Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Aug 10, 2026On August 10, 2026, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing the results from its human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film, conducted in support of the Company’s planned resubmission of its New Drug Application to …Regulation FD disclosure · Form 8-K
- May 13, 2026Credit Agreement and Guaranty On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”), consisting of a term loan in an aggregate principal amount of $55.0 million that was funded on the Effective Date …Material agreement entered · Form 8-K
- Mar 20, 2026On March 16, 2026, Aquestive Therapeutics, Inc. (the “Company”) and Lori J. Braender, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of the Company, agreed that Ms. Braender will step down from her Chief Legal Officer and Chief Compliance Officer roles and will no longer serve as an executive …Director or officer change · Form 8-K
- Mar 4, 2026On March 3, 2026, Aquestive Therapeutics, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), dated August 13, 2025, with funds managed by RTW Investments, LP ("RTW")Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #37 of 41 by RyuScore